Compare First Solar, Inc. (FSLR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs BIO-TECHNE Corp — how do they compare? First Solar, Inc. trades at $241.55 (market cap $25.72B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: First Solar, Inc. is far larger — about 2.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals.
| FSLR | TECH | |
|---|---|---|
Market Cap | $25.72B | $11.24B |
Sector | Technology | Health |
52-Week High | $318.30 | $72.29 |
52-Week Low | $180.05 | $43.31 |
Enterprise Value | $24.19B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $250.05, up 2.42% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with revenue growth from $5.22B in 2025 to projected $5.4B in 2026, net income margins above 29%, and solid cash flow generation. Recent U.S. tariff protections have boosted solar stocks, though multiple securities lawsuits create near-term uncertainty.
FSLR presents a compelling growth story with expanding profitability and favorable industry tailwinds, but investors must weigh legal overhangs against strong operational performance. The consensus price target of $282.07 suggests 13% upside potential, supported by improving debt metrics and institutional confidence despite elevated valuation multiples.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
